Abstract
Data on features of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children and adolescents are scarce. We report preliminary results of an Italian multicentre study comprising 168 laboratory-confirmed paediatric cases (median: 2.3 years, range: 1 day-17.7 years, 55.9% males), of which 67.9% were hospitalised and 19.6% had comorbidities. Fever was the most common symptom, gastrointestinal manifestations were frequent; two children required intensive care, five had seizures, 49 received experimental treatments and all recovered.
Keywords:
SARS-CoV-2 infection; children; covid-19; hydroxychloroquine; pneumonia.
MeSH terms
-
Adolescent
-
Antiviral Agents / therapeutic use
-
Betacoronavirus
-
COVID-19
-
COVID-19 Testing
-
Child
-
Child, Preschool
-
Chronic Disease / epidemiology*
-
Clinical Laboratory Techniques
-
Coinfection / epidemiology*
-
Coinfection / virology
-
Comorbidity
-
Coronavirus / isolation & purification*
-
Coronavirus Infections / diagnosis*
-
Coronavirus Infections / epidemiology
-
Coronavirus Infections / therapy
-
Diarrhea / etiology
-
Disease Outbreaks
-
Feces / virology
-
Female
-
Fever / etiology
-
Hospitals, Pediatric
-
Humans
-
Immunocompromised Host
-
Infant
-
Infant, Newborn
-
Italy / epidemiology
-
Male
-
Noninvasive Ventilation / methods
-
Pandemics / prevention & control*
-
Pneumonia, Viral / diagnosis*
-
Pneumonia, Viral / epidemiology
-
Pneumonia, Viral / therapy
-
Protease Inhibitors / therapeutic use
-
Retrospective Studies
-
SARS-CoV-2
-
Severe Acute Respiratory Syndrome / diagnosis
-
Severe Acute Respiratory Syndrome / epidemiology
-
Severe Acute Respiratory Syndrome / therapy
-
Treatment Outcome
Substances
-
Antiviral Agents
-
Protease Inhibitors